Table 3 Comparison of outcomes of contemporary SBRT
Author (Year) | N | Pt type | Dose | FU (yr) | Toxicity | Outcome | Ref |
|---|---|---|---|---|---|---|---|
King (2009) | 67 | Low-risk; PSA < 10, G < = 3 + 4; <= T2a/b | 7.25 x 5 | 2.7 | GU: Grade 4 (0 %) 3 (3 %), 2 (5 %), and 1 (23 %) respectively. Rectal Grade 3 (0 %), 2 (2 %), and 1 (12.5 %). | (5 years) 94 % relapse free survival | [24] |
Boike (2011) | 45 | PSA ≤ 20, G ≤ 7, ≤T2b | 9-10 x 5 | 2.5 | GI: 3 (2 %), 2 (16 %); GU: 3 (4 %); 2 (27 %) | [48] | |
Chen (2013) | 100 | Low/intermediate risk (8 high) | 7-7.25 x 5 | 2.3 | GU ≥2 (31 %); GI ≥ 2 (1 %) | (2 years) 99 % (31 % bounce, 21 % late transient urinary symptom flare) | [21] |
Katz (2010) | 73 | Intermediate/High Risk | 6-7 x 3 (Boost) | 2.75 | 2 (7 %) | (3 years) 89.5 % (Intermediate); 77.7 % (high) | [39] |
Suy (2010) | 24 | 6.5 x 3 (Boost) | 0.8 | GU 2 (13 %); GI 2 (4 %) | [49] | ||
Katz (2010) | 304 | Low/intermediate/high | 7-7.25 x 5 | 2.5 | Acute GU 2 (4.7 %); GI 2 (4 %); Late GU 3 (0.5 %); 2 (6 %) GI 2 (3 %) | 4 failures (16 % bounce) | [50] |
Jabarri (2012) | 38 | Low/intermediate/high | 9.5 x 4 (mono); 9.5 x 2 (boost) | 1 | Acute GU 2 (42 %); GI 2 (11 %) Late G3 3 (5 %) | No failures | [25] |
King (2013) | 1100 (pooled) | Low (58 %), intermediate (30 %) and high-risk (11 %). | 36.25 Gy in 4–5 fx | 3 | (5 years) 93 % (16 % bounce) | [19] |